文献速递慢阻肺

靶向2型炎症与上皮警报素在慢阻肺中的生物制剂前景

Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本文综述慢阻肺现有药物无法满足的治疗需求,指出20-40%患者存在2型炎症,涉及CD4+ T细胞、2型固有淋巴细胞、嗜酸性粒细胞和替代激活巨噬细胞。文章讨论上皮警报素等新靶点及2型炎症生物标志物,为生物制剂在慢阻肺中的应用提供依据。

要点

  • 20-40%慢阻肺患者表现为2型炎症,是潜在生物制剂治疗人群。
  • 现有长效支气管扩张剂、吸入激素等治疗下仍有症状和急性加重。
  • 上皮警报素是新兴治疗靶点,生物标志物有助于筛选获益患者。

核心结论

  • 慢阻肺存在显著未满足的治疗需求,靶向2型炎症和上皮警报素是新兴方向。

研究设计与样本

  • 本文为综述,检索并汇总慢阻肺现有治疗、2型炎症与上皮警报素相关文献。

主要发现

  • 20-40%的慢阻肺患者表现出2型炎症,涉及CD4+ T细胞、2型固有淋巴细胞、嗜酸性粒细胞和替代激活巨噬细胞。
  • 当前长效β2激动剂、长效抗胆碱能药、吸入糖皮质激素、磷酸二酯酶-4抑制剂和大环内酯类等治疗下,许多患者仍有持续症状和/或急性加重及肺功能进行性下降。

临床怎么用

  • 临床可关注2型炎症生物标志物以筛选可能从靶向2型炎症或上皮警报素生物制剂中获益的慢阻肺患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive inflammatory airway disease associated with a significant impact on patients' lives, including morbidity and mortality, and significant healthcare costs. Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD. However, many patients remain symptomatic, with persistent symptoms and/or acute exacerbations and progressive lung function loss. Although neutrophilic inflammation is the most common type of inflammation in COPD, 20-40% of patients with COPD exhibit type 2 inflammation, with roles for CD4+ (cluster of differentiation 4) T-helper cell type 1 cells, type 2 innate lymphoid cells, eosinophils, and alternatively activated macrophages. On the basis of the current limitations of available therapies, a significant unmet need exists in COPD management, including the need for targeted therapies to address the underlying pathophysiology leading to disease progression, such as type 2 inflammation, as well as biomarkers to help select the patients who would most benefit from the new therapies. Significant progress is being made, with evolving understanding of the pathobiology of COPD leading to novel therapeutic targets including epithelial alarmins. In this review, we describe the current therapeutic landscape in COPD, discuss unmet treatment needs, review the current knowledge of type 2 inflammation and epithelial alarmins in COPD, explore potential biomarkers of type 2 inflammation in COPD, and finally provide a rationale for incorporating therapies targeting type 2 inflammation and epithelial alarmins in COPD. Video Abstract available online at www.atsjournals.org.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Rabe KF, Rennard S, Martinez FJ, et al. Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. Am J Respir Crit Care Med. 2023. PMID: 37348121. doi:10.1164/rccm.202303-0455CI

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。